3H BIO
3H Bio is a South Korean biotechnology company (founded 2019) developing peptide-based immunotherapies for metabolic diseases. The company focuses on inducing antibody responses against apolipoprotein B100 to alter lipoprotein handling and treat obesity, fatty liver, diabetes and atherosclerosis. Development is conducted through external CRO and CDMO partnerships and in-house R&D including peptide design, organoid-based screening and patent development.
Industries
Nr. of Employees
small (1-50)
3H BIO
Suite 406, 3-9, Seongnam-daero 331 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13558, Korea
Patents
Anti-obese immunogenic hybrid polypeptides and anti-obese vaccine composition comprising the same
US-7829667-B2
View Details
Anti-obese immunogenic hybrid polypeptides and anti-obese vaccine composition comprising the same
US-7829667-B2
View DetailsProducts
ApoB100-targeting peptide immunotherapy candidate for obesity
A peptide immunotherapy candidate intended to induce antibodies against apolipoprotein B100 to reduce adipose lipid storage and provide metabolic and anti-inflammatory effects; development candidate for obesity.
Pipeline candidates for metabolic syndromes
Early-stage programs targeting obesity-related disorders, type 2 diabetes and atherosclerosis using peptide immunotherapeutic approaches; includes platform work on organoid DART screening.
ApoB100-targeting peptide immunotherapy candidate for obesity
A peptide immunotherapy candidate intended to induce antibodies against apolipoprotein B100 to reduce adipose lipid storage and provide metabolic and anti-inflammatory effects; development candidate for obesity.
Pipeline candidates for metabolic syndromes
Early-stage programs targeting obesity-related disorders, type 2 diabetes and atherosclerosis using peptide immunotherapeutic approaches; includes platform work on organoid DART screening.
Services
Collaborative execution of preclinical studies and clinical trial planning through external CRO and CDMO partners; support for regulatory filings and technology transfer.
Support and negotiation of technology transfer arrangements to advance peptide immunotherapeutic candidates into clinical manufacturing and Phase 1 trials.
Collaborative execution of preclinical studies and clinical trial planning through external CRO and CDMO partners; support for regulatory filings and technology transfer.
Support and negotiation of technology transfer arrangements to advance peptide immunotherapeutic candidates into clinical manufacturing and Phase 1 trials.
Expertise Areas
- Immunotherapeutics for metabolic diseases
- Peptide vaccine / mimotope design
- Preclinical efficacy and mechanism-of-action studies
- Organoid-based toxicity screening
Key Technologies
- Peptide-based immunotherapy
- Peptide mimotope design
- Antibody-mediated mechanism characterization
- Organoid-based DART screening
News & Updates
Company invited to present at the 43rd J.P. Morgan Healthcare Conference (2025).
Delegation meeting to discuss collaboration with Texas Global (University of Texas at Austin).
Peer-reviewed article reporting biphasic anti-ApoB100 autoantibody production in obese humans and mice (Pharmaceuticals 14(4), 330).
Preclinical study demonstrating that an ApoB100-mimetic vaccine prevents obesity and liver steatosis in a mouse model (Pharmacological Reports 69:1140-1144).
Company listed as a certificated venture company (certificate No. 20220928010037).
Multiple rounds of investment from venture partners and investors (2019-2025), supporting pipeline advancement.
Company invited to present at the 43rd J.P. Morgan Healthcare Conference (2025).
Delegation meeting to discuss collaboration with Texas Global (University of Texas at Austin).
Peer-reviewed article reporting biphasic anti-ApoB100 autoantibody production in obese humans and mice (Pharmaceuticals 14(4), 330).
Preclinical study demonstrating that an ApoB100-mimetic vaccine prevents obesity and liver steatosis in a mouse model (Pharmacological Reports 69:1140-1144).
Company listed as a certificated venture company (certificate No. 20220928010037).
Multiple rounds of investment from venture partners and investors (2019-2025), supporting pipeline advancement.